(R)-1-Boc-3-羟甲基吡咯烷 | 138108-72-2

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (R)-1-Boc-3-羟甲基吡咯烷
• 中文别名: (R)-N-BOC-3-羟甲基吡咯烷；(R)-1-叔丁氧羰基-3-羟甲基吡咯烷；(R)-1-BOC-3-羟甲基吡咯烷；(3R)-3-(羟基甲基)吡咯烷-1-羧酸叔丁酯；(R)-1-BOC-3-吡咯烷甲醇；(R)-1-N-叔丁氧羰基-3-吡咯烷甲醇；(R)-3-羟基甲基吡咯烷-1-羧酸；(R)-3-羟甲基吡咯烷-1-甲酸叔丁酯；(R)-叔丁基3-(羟甲基)吡咯烷-1-羧酸酯；N-BOC-D-BETA-脯氨醇；R-1-BOC-3羟甲基吡略烷；R-BOC-3-羟甲基吡咯烷；(R)-3-(羟甲基)吡咯烷-1-羧酸叔丁酯
• 英文名称: tert-butyl (R)-3-hydroxymethylpyrrolidine-1-carboxylate
• 英文别名: tert-butyl (3R)-3-(hydroxymethyl)pyrrolidine-1-carboxylate；(R)-tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate；(R)-3-hydroxymethylpyrrolidine-1-carboxylic acid tert-butyl ester；(R)-1-Boc-(3-hydroxymethyl)pyrrolidine；(3R)-N-tert-butyloxycarbonyl-3-hydroxymethylpyrrolidine
• CAS: 138108-72-2
• 化学式: C₁₀H₁₉NO₃
• 分子量: 201.266
• InChiKey: HKIGXXRMJFUUKV-MRVPVSSYSA-N

物化性质

• 沸点：
  289.5±13.0 °C(Predicted)
• 密度：
  1.089
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
(R)-3-Hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
(R)-3-Hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester
Ingredient name:
CAS number: 138108-72-2

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H19NO3
Molecular weight: 201.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用 (R)-1-BOC-3-羟甲基吡咯烷作为基质的导电高分子水凝胶是理想的心肌组织修复材料之一。

制备过程如下：在0°C下，向（R）-1-（叔丁氧基羰基）吡咯烷-3-羧酸（1.21 g，5.6 mmol）溶解于THF（30 mL）中的搅拌溶液中滴加硼烷THF（1.0 M，17 mL，16.9 mmol）。将所得混合物在30分钟内加热至室温，并在45℃下继续加热1小时，随后在55℃下加热90分钟。冷却反应混合物至0°C后，小心用3N HCl（30 mL）淬灭。在室温下搅拌20分钟后，使用Et2O（50 mL）萃取产物。有机层先后用饱和NaHCO3（20 mL）和盐水（20 mL）洗涤，再用Na2SO4干燥，过滤并减压浓缩后，得到 (R)-1-BOC-3-羟甲基吡咯烷（1.1 g，收率91%），呈无色油状。

反应信息

• 作为反应物：
  描述：

  (R)-1-Boc-3-羟甲基吡咯烷 在 甲醇 、 三乙胺 、 sodium hydroxide 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 (R)-N-Boc-3-四氢吡咯乙酸
  参考文献：
  名称：

  [EN] FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME
  [FR] COMPOSÉS HÉTÉROCYCLIQUES FUMAGILLOL, ET PROCÉDÉS CORRESPONDANTS DE FABRICATION ET D'UTILISATION

  摘要：

  本文披露了富马吉醇化合物及其在治疗医学疾病（如肥胖症）中的用途方法。提供了富马吉醇化合物的药物组合物和制备方法。这些化合物被认为具有对蛋氨酸氨肽酶2的活性。

  公开号：

  WO2017027684A1
• 作为产物：
  描述：

  1-叔丁氧羰基-2,3-二氢吡咯 在 acetylacetonatodicarbonylrhodium(l) 、 硼烷四氢呋喃络合物 、 氢气 、 (R,S)-binaphos 作用下， 以 四氢呋喃 、 苯 为溶剂， 60.0 ℃ 、10.13 MPa 条件下， 反应 74.0h， 生成 (R)-1-Boc-3-羟甲基吡咯烷
  参考文献：
  名称：

  手性膦-亚磷酸酯-Rh（I）配合物催化杂环烯烃的不对称加氢甲酰化。

  摘要：

  已研究了膦-亚磷酸酯-Rh（I）配合物催化的杂环烯烃的不对称加氢甲酰化反应。对称杂环烯烃（如2，5-二氢呋喃，3-吡咯啉衍生物和4,7-二氢-1,3-二氧杂环丁酮衍生物）的加氢甲酰化可在64-76％ee中将旋光性醛作为单一产物提供。不对称的底物，例如2，3-二氢呋喃和N-（叔丁氧羰基）-2-吡咯啉，给出了区域异构体的混合物。由N-（叔丁氧基羰基）-2-吡咯啉得到97％ee的N-（叔丁氧基羰基）吡咯烷-2-甲醛。2,5-二氢呋喃和N-（叔丁氧羰基）-3-吡咯啉的加氢甲酰化产物分别与2,3-二氢呋喃和N-（叔丁氧羰基）-2-吡咯啉的加氢甲酰化产物具有相反的构型。同样的催化剂。新型膦亚磷酸酯配体（R，S）-3 3'-Me（2）-BINAPHOS [=（R）-2-（二苯基膦基）-1,1'-联萘-2'-基（S）-3,3'-二甲基-1,1'-联萘-制备了2,2'-亚磷酸二乙酯]，并用NMR光谱表征了其氢化铑络合物。使用（R，S）-3

  DOI：

  10.1021/jo9624051

文献信息

• [EN] INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF<br/>[FR] DÉRIVÉ D'INDAZOLE ET PYRROLOPYRIDINE ET UTILISATION PHARMACEUTIQUE DE CELUI-CI
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2012169649A1

  公开（公告）日：2012-12-13

  The present invention relates to a novel indazole- or pyrrolopyridine-derivative, represented by the formula (1) below, that has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same. Formula (1) [wherein each substituent is as defined in claim 1]

  本发明涉及一种新型吲唑基或吡咯吡啶基衍生物，由下面的式（1）表示，该衍生物对5-羟色胺-4受体具有激动作用或部分激动作用，并且包括含有该衍生物的药物组合物。式（1）[其中每个取代基如权利要求1所定义]
• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019243527A1

  公开（公告）日：2019-12-26

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病的用途，例如tau病变，特别是阿尔茨海默病或进行性核上性麻痹症；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆症。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
  申请人：Arvinas, Inc.

  公开号：US20180099940A1

  公开（公告）日：2018-04-12

  The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

  本公开涉及双功能化合物，其用于降解和（抑制）雄激素受体。具体而言，本公开涉及包含一端结合到E3泛素连接酶的谷氨酰腺苷环配体，另一端结合到雄激素受体的部分的化合物，使得雄激素受体与泛素连接酶靠近，以实现雄激素受体的降解（和抑制）。本公开展示了与根据本公开涉及的化合物相关的广泛的药理活性范围，与雄激素受体的降解/抑制一致。
• 联苯衍生物及其制备方法
  申请人：东亚ST 株式会社

  公开号：CN105555761B

  公开（公告）日：2018-12-11

  本发明提供了新的联苯衍生物、其同分异构体或其药学上可接受的盐，它们的制备方法，以及包含它们的药物组合物。本发明的新的联苯衍生物、其同分异构体或药学上可接受的盐起到毒蕈碱M3受体拮抗剂的作用，并且因此可用于预防或治疗选自以下的疾病：慢性阻塞性肺病、哮喘、肠易激综合征、尿失禁、鼻炎、痉挛性结肠炎、慢性膀胱炎、阿尔兹海默病、老年痴呆、青光眼、精神分裂症、胃食管返流病、心律失常和多涎综合征。
• Transition-metal-free synthesis of 3-(1-pyrrolidinyl)quinolines and 3-(1-pyrrolidinyl)quinoline 1-oxides via a one-pot reaction of 3-(1-pyrrolidinyl)crotonates with nitrobenzenes
  作者：Robert Bujok、Piotr Cmoch、Zbigniew Wróbel、Krzysztof Wojciechowski

  DOI：10.1039/c6ob02658c

  日期：——

  tert-butyl 3-(1-pyrrolidinyl)crotonate adds to nitrobenzenes to form σH-adducts, which in the presence of pivaloyl chloride and triethylamine are converted into 3-(1-pyrrolidinyl)quinolines or 3-(1-pyrrolidinyl)quinoline 1-oxides depending on the nitrobenzene structure. This is the first methodology in which a quinoline ring is constructed from a substrate bearing a pyrrolidinyl ring. Starting from optically

  的碳负离子叔丁基3-（1-吡咯烷基）丁烯酸增加了硝基苯形成σ ħ -adducts，其在新戊酰氯的存在下和三乙胺转化成3-（1-吡咯烷基）喹啉或3-（1-吡咯烷基）喹啉1-氧化物取决于硝基苯的结构。这是从带有吡咯烷基环的底物构建喹啉环的第一种方法。从光学纯的烯胺开始，该方法允许合成相应的手性产物而无需外消旋化。